Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

Withdrawn before enrolling · Early Phase 1

Conditions studied: Major Depressive Disorder, Coronary Artery Disease

In brief

This is a preliminary, open-label, clinical trial designed to assess the efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients with coronary artery disease. In addition, the study will assess the effects of vortioxetine on heart rate variability in these patients.

Key facts

Study ID

NCT02454426

Run by

Thomas Jefferson University

People needed

0

Starts

2016-04-01

Expected to finish

2016-06-01

Last updated by the study team

2016-08-25

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• DSM-5 diagnosis of a major depressive disorder based on clinical evaluation by the study psychiatrist
• At least moderate severity of depression as indicated by a Montgomery-Asberg Depression Rating Scale (MADRS) score of 22 or greater
• History of coronary artery disease as defined by:
• History of coronary stenosis in one or more vessels that is greater ≥ 70% by coronary angiography or CT angiogram, OR
• History of abnormal stress test (at least medium-sized, moderate, reversible defect), OR
• History of documented myocardial infarction including ST elevation myocardial infarction or non-ST elevation myocardial infarction (with elevated troponins), OR
• Evidence of adequate treatment of the coronary artery disease as defined by at least one of the following that was done at least six months prior to the Screening visit, AND was followed by the patient being clinically stable in the opinion of a cardiologist who has evaluated the case:
• Coronary artery bypass grafting (CABG)
• Percutaneous coronary intervention (PCI)/ stenting
• Adequate management with optimal medical treatment (such as one or more of the following medications: aspirin, beta blockers, a statin (e.g., atorvastatin), and either an ACE inhibitor or an angiotensin-receptor blocker.)
• Key Exclusion Criteria:
• Psychiatric Exclusion Criteria:
• Patients who in the past have failed to respond to a trial of vortioxetine at the minimum recommended dose (10 mg/day) or greater taken for at least six weeks, or had unacceptable adverse effects while taking vortioxetine.
• Patients must not have failed treatment with more than one antidepressant (taken at an adequate dose and for at least six weeks) in the current episode of major depressive disorder (i.e., did not have > 50% reduction in severity of depression based on patient history)
• Patients with a current primary DSM-5 diagnosis of:
• i) Delirium, dementia, amnestic, or other cognitive disorder; ii) Eating Disorder (including Anorexia Nervosa or Bulimia); iii) Obsessive Compulsive Disorder; iv) Panic Disorder; v) Post-Traumatic Stress Disorder (PTSD);
• Current or past (lifetime) DSM-5 diagnosis of:
• i) Bipolar I or II disorder; ii) Hypomanic episode iii) Substance-induced manic or hypomanic episode iii) Schizophrenia or other psychotic disorder
• Cardiovascular Exclusion Criteria:
• Patients who have had a myocardial infarction within 30 days of the screening visit
• Any cardiovascular condition that is unstable or decompensated
• In the opinion of the Investigators, the patient is at significant risk of cardiovascular adverse events
• Coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)/ stenting within three months of the screening visit
• Admission to a hospital for any cardiac condition within three months of the screening visit
• Decompensated heart failure within 6 months of the screening visit

Where it is running

• Thomas Jefferson University — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.